Prescription medication · Tetracycline Antibiotic
omadacycline
Also sold as Nuzyra. Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.
Data updated 2026-05-15
- 1,476
- FDA reportsRarely reported
- 1
- InteractionFew interactions
- Rx
- Availability
What the data shows
omadacycline (Nuzyra) is a prescription Tetracycline Antibiotic, among the least-reported drugs the FDA tracks (1,476 FDA reports), with 1 documented drug interaction.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
omadacycline (Nuzyra) is a prescription Tetracycline Antibiotic. Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.
Nuzyra is an antibiotic medicine. It fights certain bacteria to treat infections.
Verify with FDA → · CMS NADAC pricing →
What it does
Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.
Common side effects
Nausea, Vomiting, Reactions where the IV was given
Key warnings
Nuzyra may cause an imbalance in the number of deaths in patients with pneumonia.
The sections below are summarized in plain English from omadacycline's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Nuzyra is a tetracycline antibiotic. It stops bacteria from growing by interfering with their protein production. This helps your body fight off the infection.
How to Take It
Nuzyra can be given as an IV injection or taken as a pill. For pills, fast for 4 hours before taking it with water. After taking the pill, don't eat or drink anything (except water) for 2 hours. Also, avoid dairy, antacids, and multivitamins for 4 hours after taking the pill. Treatment lasts 7 to 14 days.
This is a plain-language summary of omadacycline's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
Nuzyra can cause tooth discoloration and bone problems in unborn babies. Breastfeeding is not recommended while using Nuzyra.
This is a plain-language summary of omadacycline's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule.
This is a plain-language summary of omadacycline's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store Nuzyra at room temperature, away from moisture and heat. Do not freeze.
Side Effects (from patient reports)
Based on 1,476 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for omadacycline, by number of reports
- Nausea
Nausea
245 reports
- Vomiting
Vomiting
152 reports
- Diarrhoea
Diarrhoea
107 reports
- Incorrect Product Administration Duration 76
Incorrect Product Administration Duration
76 reports
- Rash 70
Rash
70 reports
- Incorrect Dose Administered 68
Incorrect Dose Administered
68 reports
- Death 66
Death
66 reports
- Dyspnoea 65
Dyspnoea
65 reports
- Fatigue 56
Fatigue
56 reports
- Hospitalisation 55
Hospitalisation
55 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for omadacycline each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where omadacycline sits
omadacycline has more FDA adverse-event reports than 9% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is omadacycline; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,476 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2017–2025.
Total Reports
1,476
Reports Mentioning Death
101
6.8% of reports — not proof of cause
Hospitalization Reports
329
Top Indication
Mycobacterium Abscessus Infection
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | NAUSEA | 245 |
| 3 | VOMITING | 152 |
| 5 | DIARRHOEA | 107 |
| 6 | INCORRECT PRODUCT ADMINISTRATION DURATION | 76 |
| 7 | RASH | 70 |
| 8 | INCORRECT DOSE ADMINISTERED | 68 |
| 9 | DEATH | 66 |
| 10 | DYSPNOEA | 65 |
| 11 | FATIGUE | 56 |
| 12 | HOSPITALISATION | 55 |
| 13 | HEADACHE | 52 |
| 14 | PRURITUS | 52 |
| 15 | DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 48 |
| 16 | COUGH | 44 |
| 18 | ASPARTATE AMINOTRANSFERASE INCREASED | 41 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Nuzyra may cause an imbalance in the number of deaths in patients with pneumonia. The cause of this is not known, so your doctor will watch you closely. Nuzyra can also cause tooth discoloration and affect bone growth in children under 8 and unborn babies. Diarrhea can occur, so tell your doctor if you have diarrhea while taking Nuzyra.
Known Drug Interactions
( 7.1 ) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1) ].
Mechanism: Bismuth subsalicylate interferes with how your body takes in the antibiotic, making the medicine less effective at fighting infection.
What to do: Avoid taking these two medicines at the same time so the antibiotic can work correctly.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
What should I avoid while taking Nuzyra?
Can I take Nuzyra with food?
How long will I need to take Nuzyra?
What if I feel better before finishing all my Nuzyra?
Can Nuzyra affect my teeth?
Can Nuzyra affect my bones?
What should I do if I get diarrhea while taking Nuzyra?
Can I take antacids with Nuzyra?
Will Nuzyra interact with other medications I'm taking?
What happens if I take too much Nuzyra?
What are the common side effects of omadacycline?
Does omadacycline interact with other medications?
What drug class is omadacycline?
Is omadacycline safe during pregnancy?
Related Medications in Tetracycline Antibiotic
Other drugs grouped near omadacycline - same-class peers and common alternatives.
amikacin
Amikin
Amikacin is an antibiotic medicine.
Compare with omadacycline →
amoxicillin
Amoxil
Amoxicillin and Clavulanate Potassium is a combination medicine used to fight bacterial infections.
Compare with omadacycline →
amoxicillin/clavulanate
Augmentin
Augmentin is a combination of two medicines, amoxicillin and clavulanate.
Compare with omadacycline →
ampicillin/sulbactam
Unasyn
Unasyn is a combination of two antibiotics that fights bacteria in your body.
Compare with omadacycline →
azithromycin
Zithromax, Z-Pack
Azithromycin is an antibiotic that fights bacteria.
Compare with omadacycline →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on omadacycline
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for omadacycline
The FDA label for omadacycline (sold under brand names such as Nuzyra) classifies it as a prescription-only medication in the Tetracycline Antibiotic class. Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection. Official labeling lists 9 commonly reported side effects, including Nausea, Vomiting, Reactions where the IV was given.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,476 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: March 31, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages